Comparison
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 vs 4 Hydroxyphenylacetic Aciduria C1848680
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Fetal Androgens Excess and 4 Hydroxyphenylacetic Aciduria for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
A condition where an XX fetus produces excess male hormones, often from adrenal gland abnormalities, leading to atypical genital development. It is identified at birth. Treatment typically includes hormone therapy and possible surgery.
4 Hydroxyphenylacetic Aciduria C1848680
A metabolic disorder where the body cannot properly break down certain amino acids. Typically detected in infancy through screening. Treated with dietary modifications and monitoring.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
0-0
4 Hydroxyphenylacetic Aciduria C1848680
Variable
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
severe
4 Hydroxyphenylacetic Aciduria C1848680
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
Chronic
4 Hydroxyphenylacetic Aciduria C1848680
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
No
4 Hydroxyphenylacetic Aciduria C1848680
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
reproductive
4 Hydroxyphenylacetic Aciduria C1848680
metabolic
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
endocrine
4 Hydroxyphenylacetic Aciduria C1848680
metabolic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-fetal-androgens-excess-C5680189 and 4-hydroxyphenylacetic-aciduria-C1848680 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 | 4 Hydroxyphenylacetic Aciduria C1848680 | Discriminating power |
|---|---|---|---|
| Genital appearance | Atypical genital development may be recognized at birth. | No genital abnormality is established by the supplied data. | High |
| Metabolic signs | Not primarily described as an amino-acid breakdown disorder. | May reflect impaired handling of certain amino acids, often found in infancy. | High |
| Onset pattern | Source onset is at birth. | Onset is listed as variable and often detected through infant screening. | Moderate |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 when
Newborn with atypical genitalia and suspected androgen exposure
The reproductive and endocrine pattern matches the left concept.
High
Suspected adrenal source of fetal androgen excess
The source specifically links excess androgens with possible adrenal abnormality.
Moderate
Need for sex-development specialist assessment
Management may involve hormones and decisions about surgery, requiring specialist care.
Moderate
Choose 4 Hydroxyphenylacetic Aciduria C1848680 when
Infant screening suggests an amino-acid-related abnormality
The right concept is typically detected through infancy screening.
Moderate
Urine organic-acid testing shows 4-hydroxyphenylacetic acid elevation
This supports the named biochemical abnormality but does not alone prove its cause.
Moderate
Dietary management is being considered
The source describes dietary modification and monitoring, guided by a clinician.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 | 4 Hydroxyphenylacetic Aciduria C1848680 | Interpretation |
|---|---|---|---|
| Newborn genital and endocrine evaluation | May show atypical genitalia and evidence of androgen excess. | No specific genital or endocrine abnormality is established. | Supports the left concept when clinically correlated. |
| Urine organic-acid analysis | Not described as the defining test. | May show elevated 4-hydroxyphenylacetic acid. | An abnormal result requires cause assessment and is not itself a complete diagnosis. |
| Amino-acid or metabolic evaluation | Not the primary described pathway. | May investigate impaired amino-acid breakdown. | Exact cutoffs and diagnostic criteria are not supplied. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
- Outcome
- Potentially substantial lifelong impact; exact outcomes are not established.
- Factors
- Cause of androgen excess, endocrine control, and coordinated specialist care.
4 Hydroxyphenylacetic Aciduria C1848680
- Outcome
- Listed as moderate, but individual outcome is not established.
- Factors
- Underlying cause, dietary response, and monitoring.
Time frame: Both are described as chronic; precise timelines are unavailable.
Do not infer mortality or treatment response from these sparse data.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental or identity-related impact | Atypical sex development can have lasting medical and psychosocial effects. No such effect is established in the source. Care should be individualized and specialist-led. |
| Metabolic imbalance | Not described as the main complication. Possible if the underlying metabolic problem is untreated or poorly monitored. Specific complication rates are not established. |
| Treatment-related burden | Hormone therapy and possible surgery may require long-term follow-up. Dietary changes and monitoring may be needed. Neither treatment plan should be inferred beyond the source. |
Patient education highlights
- HighDifferent conditions
One concerns fetal androgen excess and sex development; the other concerns a metabolic urine abnormality.
- HighSpecialist interpretation
Abnormal results and clinical findings need clinician confirmation before diagnosis or treatment.
- MediumFollow-up
Both are described as chronic and may require ongoing monitoring tailored to the individual.